Overexpression of Nrf2 attenuates Carmustine-induced cytotoxicity in U87MG human glioma cells

Abstract

BackgroundMalignant glioma is one of the most devastating tumors in adults with poor patient prognosis. Notably, glioma often exhibits resistance to conventional chemotherapeutic approaches, complicating patient treatments. However, the molecular mediators involved in tumor chemoresistance remain poorly defined, creating a barrier to the successful management of glioma. In the present study, we hypothesized that the antioxidant transcription factor, Nrf2 (nuclear factor erythroid-derived 2 like 2), attenuates glioma cytotoxicity to Carmustine (BCNU), a widely used chemotherapeutic agent known to modulate cellular oxidative balance.MethodsTo test the hypothesis, we employed human malignant glioma cell line, U87MG and overexpression of Nrf2 in glioma cells was achieved using both pharmacological and genetic approaches.ResultsNotably, induction of Nrf2 was associated with increased expression of heme oxygenase-1 (HO-1), a stress inducible enzyme involved in anti-oxidant defense. In addition, over expression of Nrf2 in U87MG cells significantly attenuated the cytotoxicity of Carmustine as evidenced by both cellular viability assay and flow cytometry analysis. Consistent with this, antioxidants such as glutathione and N-acetyl cysteine significantly reduced Carmustine mediated glioma cytotoxicity.ConclusionsTaken together, these data strongly implicate an unexplored role of Nrf2 in glioma resistance to Carmustine and raise the possible use of Nrf2 inhibitors as adjunct to Carmustine for the treatment of malignant glioma.Electronic supplementary materialThe online version of this article (doi:10.1186/s12885-015-1134-z) contains supplementary material, which is available to authorized users.

Targeting autophagy to sensitive glioma to temozolomide treatment

“…In addition, a significant negative correlation has been found between Nrf2 expression and the outcome for GBM patients [ 114 ]. Recent studies have reported that development of chemoresistance is associated with the constitutive activation of the Nrf2-mediated signaling pathway in many types of cancer cells, including gliomas [ 115 ]. Chrysin, a potent Nrf2 inhibitor, could effectively reverse the resistance of an anticancer drug by down-regulating the PI3K/Akt and ERK pathways [ 116 ].…”

Long noncoding RNA TSLNC8 suppresses cell proliferation and metastasis and promotes cell apoptosis in human glioma

“…The overall median survival for patients with glioma is between 16 to 18 months (3,4). Notable advances in the therapeutic strategies of glioma have been made in the last decade, including neurosurgical approaches, chemotherapy and radiotherapy; however, the prognosis of glioma remains poor, mainly due to the fact that glioma cells are highly aggressive and capable of infiltrating adjacent normal brain tissue, leading to the failure of complete dissection of the tumor by surgery in the brain (5,6). Recurrence and resistance to chemotherapy are another two influential factors responsible for poor prognosis (7)(8)(9).…”

Long noncoding RNA eosinophil granule ontogeny transcript inhibits cell proliferation and migration and promotes cell apoptosis in human glioma

“…3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay (Promega Corp., Pittsburgh, PA, USA) was used to measure cell growth abilities according to the manufacturer's protocol. Briefly, U251 and U87 cells were seeded in 96-well plates at an initial density of 5x10 3 /well in DMEM supplemented with 10% FBS in a humidified incubator containing 5% CO 2 . Each experimental group of cells was spread into six wells and the cultural medium was replaced every other day.…”

“…According to a population-based investigation, the overall median survival duration for patients with malignant glioma is ~15 months (2). Despite significant advances in the therapeutic strategies of glioma, including neurosurgical approaches, chemotherapy and radiotherapy, the prognosis of patients with malignant glioma remains poor, primarily due to the fact that malignant glioma cells are highly aggressive and capable of infiltrating into adjacent normal brain tissue, leading to the eventual failure of complete surgical dissection of the tumor (3,4). Recurrence and resistance to chemotherapy are to be claimed two influential factors for prognosis (5,6).…”